Evaxion Biotech A/S Adr (EVAX) has released an update.
Evaxion Biotech A/S, also operating under the secondary name NovVac A/S, aims to advance software for developing immune therapies and vaccines. The company’s share capital stands at DKK 54,110,546, divided into non-negotiable shares with no special rights for any shareholder. Furthermore, the board is authorized until April 2029 to issue warrants and increase share capital by up to DKK 10,000,000 to facilitate strategic incentives for directors, executives, and key employees.
For further insights into EVAX stock, check out TipRanks’ Stock Analysis page.
